2018
Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study
Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood 2018, 132: 3580. DOI: 10.1182/blood-2018-99-119272.Peer-Reviewed Original ResearchStatin usersImpact of statinsLog-rank testRisk of thrombosisOverall survivalPercentage of daysPV patientsMyeloproliferative neoplasmsPV diagnosisMultivariate Cox proportional hazards modelContinuous Medicare Parts ACox proportional hazards modelCardiovascular risk factorsEnd Results-MedicareErythropoietin-independent erythroid colony formationBetter overall survivalKaplan-Meier curvesType of statinPopulation-based cohortNumber of phlebotomiesEnd of studyProportional hazards modelPart DMedicare Part AHealth maintenance organization
2015
Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)
Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). Blood 2015, 126: 873. DOI: 10.1182/blood.v126.23.873.873.Peer-Reviewed Original ResearchDisability Status ScoreOverall survivalMyelodysplastic syndromeMDS patientsCost of careStudy cohortLack of associationHistologic subtypeStatus scoreMedicare beneficiariesEnd Results-Medicare databaseProportional hazards regression modelsOverall study cohortMedian overall survivalOutcomes of patientsElixhauser comorbidity scoreDate of diagnosisEntire study cohortKaplan-Meier methodHazards regression modelsDisease-related costsNon-white raceEnd of studyDate of deathMedicare Part APatient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D
Davidoff AJ, Hendrick FB, Zeidan AM, Baer MR, Stuart BC, Shenolikar RA, Gore SD. Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D. JCO Oncology Practice 2015, 11: e190-e198. PMID: 25563701, PMCID: PMC4371123, DOI: 10.1200/jop.2014.001527.Peer-Reviewed Original ResearchConceptsErythropoiesis-stimulating agentsLow-income subsidyMyelodysplastic syndromePhysician's officePart DOOP paymentsErythropoiesis stimulating agentsPart D claimsMedicare Part APatient cost sharingMedicare Part DESA useAnemia managementD claimsInjected medicationsDiagnosis codesMultivariable modelHome injectionMedicare beneficiariesPart BPatientsPocket costsPatient accessPrescription benefitsCost sharing
2013
Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).
Gore S, Davidoff A, Hendrick F, Duong V, Stuart B, Baer M, Shenolikar R, Zeidan A. Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO). Journal Of Clinical Oncology 2013, 31: e17584-e17584. DOI: 10.1200/jco.2013.31.15_suppl.e17584.Peer-Reviewed Original ResearchOral iron chelation therapyIron chelation therapyTransfusional iron overloadMyelodysplastic syndromeDose adequacySupportive care drugsProportional hazards modelMedicare Part ATherapeutic equipoiseCohort entryHazard ratioMost patientsRBC transfusionMDS patientsOral chemotherapyAdequate doseCare drugsIron overloadLogistics of administrationChelation therapyOral formulationHazards modelMedicare beneficiariesParenteral administrationTreatment duration
2012
Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes
Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes. Blood 2012, 120: 3837. DOI: 10.1182/blood.v120.21.3837.3837.Peer-Reviewed Original ResearchErythropoiesis-stimulating agentsTransfusion independenceTransfusion useMyelodysplastic syndromeRisk groupsTransfusion statusLens useObservational studyClaims dataLarge population-based observational studiesResponse rateIntermediate-risk myelodysplastic syndromesPopulation-based observational studyICD-9-CM codesCycles of therapyInitiation of lenalidomidePoor performance statusReceipt of transfusionClinical trial evidenceInitiation of treatmentAge 75 yearsTransfusion-dependent anemiaEnd of studyZIP Code-level measuresMedicare Part AMedicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: A Medicare-Database Analysis.
Davidoff A, Hendrick F, Stuart B, Zeidan A, Shenolikar R, Gore S, Baer M. Medicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: A Medicare-Database Analysis. Blood 2012, 120: 3176. DOI: 10.1182/blood.v120.21.3176.3176.Peer-Reviewed Original ResearchErythropoiesis stimulating agentsLow-income subsidyPart D claimsMyelodysplastic syndromePart D plansPrior authorizationStudy cohortD claimsOOP paymentsMDS diagnosisPart DUse of ESAsPart D.Lower-risk myelodysplastic syndromesPoor functional statusChronic renal failureD plansErythropoiesis-stimulating agentsMultivariate logistic regressionTreatment of anemiaPart D coverageMedicare Part APlan characteristicsPrescription drug coveragePatient-level observations